Circassia paying £188m for two asthma firms, but it's still an allergy specialist
This article was originally published in Scrip
Circassia is acquiring two asthma product developers for more than £188m but this doesn't mean the company is dropping its allergy focus.
You may also be interested in...
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
Circassia is shifting its focus on its respiratory portfolio following the disappointing Phase III results of its cat allergy drug in June, which saw the company’s share price plummet by more than 60%.
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.